GBIM:OTCMKTS
GlobeImmune Inc
0,00010 US$
0,00%
(0,00) 1K
29-sen, 15:48:52 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoGBIM tikeri uchun statistika yaratilmoqda...
Bozor kapitali
580,00
Oʻrtacha hajm
1,74 ming
Hajmi
0,00
52 haftalik eng yuqori
0,04 US$
52 haftalik eng past
0,00 US$
Muomaladagi aksiyalar
5,75 mln
Xodimlar soni
22
Bozor kapitali
580,00
Oʻrtacha hajm
1,74 ming
Hajmi
0,00
52 haftalik eng yuqori
0,04 US$
52 haftalik eng past
0,00 US$
Muomaladagi aksiyalar
5,75 mln
Xodimlar soni
22
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
ACROFAN USA
·
5 daqiqa oldin
BCRF Launches $100 Million Venture Program for Breast Cancer: NYSE Content Update
The Daily News | Texas' Oldest Newspaper
·
25 daqiqa oldin
Traders work on the floor of the NYSE in New York
Simply Wall Street
·
6 daqiqa oldin
Werner Enterprises (WERN) Secures A Larger Credit Line, Is It Still Below Fair Value?
The Motley Fool
·
28 daqiqa oldin
S&P 500 Stock Casey's Dropped 30% in Its Biggest Pullback Since the Great Recession -- Here's Why I'm Buying More
Profil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
GlobeImmune Inc haqida
CEO-
Xodimlar soni22
Asos solingan1-yan, 1995
Bosh ofislarLouisville, Kolorado, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytglobeimmune.com